BR9611311A - Derivados de 5-fenil-3-(piperidin-4-il)-1,3,4-oxadiazol-2(3h)-ona úteis como ligantes dos receptores 5-ht4 ou h3 - Google Patents

Derivados de 5-fenil-3-(piperidin-4-il)-1,3,4-oxadiazol-2(3h)-ona úteis como ligantes dos receptores 5-ht4 ou h3

Info

Publication number
BR9611311A
BR9611311A BR9611311A BR9611311A BR9611311A BR 9611311 A BR9611311 A BR 9611311A BR 9611311 A BR9611311 A BR 9611311A BR 9611311 A BR9611311 A BR 9611311A BR 9611311 A BR9611311 A BR 9611311A
Authority
BR
Brazil
Prior art keywords
oxadiazole
piperidin
phenyl
receptor ligands
derivatives useful
Prior art date
Application number
BR9611311A
Other languages
English (en)
Portuguese (pt)
Inventor
Samir Jegham
Alistair Lochead
Frederic Galli
Alain Nedelec
Axelle Solignac
Cruz Laurence De
Original Assignee
Synthelabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9513252A external-priority patent/FR2741069B1/fr
Priority claimed from FR9513253A external-priority patent/FR2741070B1/fr
Priority claimed from FR9602663A external-priority patent/FR2745574B1/fr
Application filed by Synthelabo filed Critical Synthelabo
Publication of BR9611311A publication Critical patent/BR9611311A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
BR9611311A 1995-11-09 1996-11-05 Derivados de 5-fenil-3-(piperidin-4-il)-1,3,4-oxadiazol-2(3h)-ona úteis como ligantes dos receptores 5-ht4 ou h3 BR9611311A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FR9513252A FR2741069B1 (fr) 1995-11-09 1995-11-09 Derives de 5-phenyl-3-(piperidin-4-yl)-1,3,4-oxadiazol-2(3h) -one, leur preparation et leur application en therapeutique
FR9513253A FR2741070B1 (fr) 1995-11-09 1995-11-09 Derives de 5-phenyl-3-(piperidin-4-yl)-1,3,4-oxadiazol-2(3h) -one, leur preparation et leur application en therapeutique
FR9602663A FR2745574B1 (fr) 1996-03-04 1996-03-04 Derives de 5-phenyl-3-(piperidin-4-yl)-1, 3, 4-oxadiazol-2 (3h)-one, leur preparation et leur application en therapeutique
PCT/FR1996/001730 WO1997017345A1 (fr) 1995-11-09 1996-11-05 Derives de 5-phenyl-3-(piperidin-4-yl)-1,3,4-oxadiazol-2(3h)-one, utiles comme ligands des recepteurs 5-ht4 ou h¿3?

Publications (1)

Publication Number Publication Date
BR9611311A true BR9611311A (pt) 1999-06-29

Family

ID=27253120

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9611311A BR9611311A (pt) 1995-11-09 1996-11-05 Derivados de 5-fenil-3-(piperidin-4-il)-1,3,4-oxadiazol-2(3h)-ona úteis como ligantes dos receptores 5-ht4 ou h3

Country Status (29)

Country Link
US (1) US5929089A (enExample)
EP (1) EP0863897B1 (enExample)
JP (1) JP4263240B2 (enExample)
CN (1) CN1077891C (enExample)
AR (1) AR004708A1 (enExample)
AT (1) ATE181328T1 (enExample)
AU (1) AU707325B2 (enExample)
BG (1) BG63463B1 (enExample)
BR (1) BR9611311A (enExample)
CA (1) CA2236357C (enExample)
CO (1) CO4770968A1 (enExample)
CZ (1) CZ287268B6 (enExample)
DE (1) DE69602970T2 (enExample)
EE (1) EE03487B1 (enExample)
ES (1) ES2135934T3 (enExample)
GR (1) GR3030823T3 (enExample)
HU (1) HUP0001168A3 (enExample)
IL (1) IL124364A (enExample)
MX (1) MX9803696A (enExample)
NO (1) NO309606B1 (enExample)
NZ (1) NZ321626A (enExample)
PL (1) PL186204B1 (enExample)
RU (1) RU2167160C2 (enExample)
SI (1) SI0863897T1 (enExample)
SK (1) SK282335B6 (enExample)
TR (1) TR199800827T2 (enExample)
TW (1) TW371303B (enExample)
UA (1) UA50748C2 (enExample)
WO (1) WO1997017345A1 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW467902B (en) * 1996-07-31 2001-12-11 Bristol Myers Squibb Co Diphenyl heterocycles as potassium channel modulators
FR2762316B1 (fr) * 1997-04-18 1999-12-17 Sanofi Synthelabo Derives de 5-aryl-3-(8-azabicyclo[3.2.1] octan-3-yl)-1,3,4- oxadiazol-2(3h)-one, leur preparation et leur application en therapeutique
EP0980370A1 (fr) * 1997-05-06 2000-02-23 Sanofi-Synthelabo Derives de 5-phenyl-1,3,4-oxadiazol-2(3h)-one et leur utilisation comme ligands 5-ht4
FR2763068B1 (fr) 1997-05-06 1999-06-04 Synthelabo Derives de 3-(pyrrolidin-3-yl)-1,3,4-oxadiazol-2(3h)-one, leur preparation et leur application en therapeutique
GB9715816D0 (en) * 1997-07-25 1997-10-01 Black James Foundation Histamine H receptor ligands
US6960579B1 (en) 1998-05-19 2005-11-01 Alcon Manufacturing, Ltd. Serotonergic 5HT7 receptor compounds for treating ocular and CNS disorders
DK1112106T3 (da) 1998-09-18 2005-12-12 Alcon Mfg Ltd Serotonerge 5HT2-agonister til behandling af glaukom
EP1173168A2 (en) * 1999-04-28 2002-01-23 Respiratorius AB Compound for use as a medicament for treatment of disorders involving bronchocontraction
CN1355698A (zh) * 1999-06-15 2002-06-26 呼吸器有限公司 可用作治疗有关支气管收缩的机能障碍的药物的化合物
ATE319696T1 (de) 2000-08-08 2006-03-15 Ortho Mcneil Pharm Inc Nicht-imidazol aryloxyalkylamine als h3 rezeptor liganden
KR100852362B1 (ko) 2000-08-08 2008-08-14 오르토-맥네일 파마슈티칼, 인코퍼레이티드 비-이미다졸 아릴옥시피페리딘
AU2001281119A1 (en) 2000-08-08 2002-02-18 Ortho-Mcneil Pharmaceutical, Inc. Bicyclic compounds as h3 receptor ligands
US7208497B2 (en) 2001-07-02 2007-04-24 Novo Nordisk A/S Substituted piperazines and diazepanes
ATE449090T1 (de) 2001-07-02 2009-12-15 High Point Pharmaceuticals Llc Substituierte piperazin- und diazepanderivate zur verwendung als histamin h3 rezeptormodulatoren
US20030186963A1 (en) 2001-09-14 2003-10-02 Dorwald Florencio Zaragoza Substituted piperidines
ATE450508T1 (de) * 2001-09-14 2009-12-15 High Point Pharmaceuticals Llc Substituierte piperidinen mit selektiver bindungsfähigkeit zu histamin h3-rezeptoren
EP1430027B1 (en) 2001-09-14 2010-09-01 High Point Pharmaceuticals, LLC Novel aminoazetidine, -pyrrolidine and -piperidine derivatives
US6673829B2 (en) 2001-09-14 2004-01-06 Novo Nordisk A/S Aminoazetidine,-pyrrolidine and -piperidine derivatives
US7064135B2 (en) 2001-10-12 2006-06-20 Novo Nordisk Inc. Substituted piperidines
EP2243776A1 (en) 2001-10-12 2010-10-27 High Point Pharmaceuticals, LLC Substituted piperidines and their use for the treatment of diseases related to the histamine H3 receptor
US7005448B2 (en) 2001-12-14 2006-02-28 Alcon, Inc. Aminoalkyl-benzofuran-5-ol compounds for the treatment of glaucoma
US20030236259A1 (en) * 2002-02-05 2003-12-25 Rolf Hohlweg Novel aryl- and heteroarylpiperazines
GB0211230D0 (en) * 2002-05-16 2002-06-26 Medinnova Sf Treatment of heart failure
US7332508B2 (en) * 2002-12-18 2008-02-19 Novo Nordisk A/S Substituted homopiperidine, piperidine or pyrrolidine derivatives
GB0325956D0 (en) * 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
AU2005254800B2 (en) 2004-06-15 2010-12-09 Pfizer Inc. Benzimidazolone carboxylic acid derivatives
US7737163B2 (en) 2004-06-15 2010-06-15 Pfizer Inc. Benzimidazolone carboxylic acid derivatives
EP2386554A1 (en) 2005-07-04 2011-11-16 High Point Pharmaceuticals, LLC Compounds active at the histamine H3 receptor
DE602006011363D1 (de) * 2005-12-01 2010-02-04 Hoffmann La Roche Heteroaryl-substituierte piperidin-derivate als l-cpt1-hemmer
EP2079732B9 (en) 2006-05-29 2012-03-21 High Point Pharmaceuticals, LLC 3- (1, 3-benz0di0x0l-5-yl) -6- (4-cyclopropylpiperazin-1-yl) -pyridazine, its salts and solvates and its use as histamine h3 receptor antagonist
EP2014656A3 (en) * 2007-06-11 2011-08-24 High Point Pharmaceuticals, LLC New heteocyclic h3 antagonists
PT2758394E (pt) * 2011-09-19 2015-04-22 Suven Life Sciences Ltd Compostos heteroarilo como ligandos de recetores 5-ht4

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5055476A (en) * 1990-08-13 1991-10-08 Hoechst-Roussel Pharmaceuticals Incorporated 3-(1,2-benzisoxazol-3-yl)-4-pyridinamines and derivatives
NZ243993A (en) * 1991-08-20 1994-10-26 Smithkline Beecham Plc Pharmaceutical compositions having 5-ht4 receptor antagonist activity and selected compounds having such activity
US5580885A (en) * 1991-09-12 1996-12-03 Smithkline Beecham P.L.C. 5-HT4 receptor antagonists
AU667874B2 (en) * 1992-02-06 1996-04-18 Smithkline Beecham Plc Benzopyran, benzothiopyran and benzofuran derivatives as 5-HT4 antagonists
GB9219163D0 (en) * 1992-09-10 1992-10-28 Smithkline Beecham Plc Pharmaceuticals
JPH06157518A (ja) * 1992-11-27 1994-06-03 Yamanouchi Pharmaceut Co Ltd 新規なオキサジアゾール誘導体又はその塩

Also Published As

Publication number Publication date
AR004708A1 (es) 1999-03-10
CZ287268B6 (en) 2000-10-11
HUP0001168A3 (en) 2001-07-30
PL326671A1 (en) 1998-10-12
BG102412A (en) 1999-08-31
EP0863897A1 (fr) 1998-09-16
CO4770968A1 (es) 1999-04-30
EE03487B1 (et) 2001-08-15
SK59998A3 (en) 1998-11-04
HK1016165A1 (en) 1999-10-29
PL186204B1 (pl) 2003-11-28
IL124364A0 (en) 1998-12-06
SK282335B6 (sk) 2002-01-07
NZ321626A (en) 1998-10-28
DE69602970T2 (de) 2000-01-20
MX9803696A (es) 1998-09-30
AU707325B2 (en) 1999-07-08
CA2236357C (en) 2006-10-17
CN1077891C (zh) 2002-01-16
GR3030823T3 (en) 1999-11-30
HUP0001168A2 (hu) 2001-04-28
CA2236357A1 (en) 1997-05-15
US5929089A (en) 1999-07-27
BG63463B1 (bg) 2002-02-28
TW371303B (en) 1999-10-01
RU2167160C2 (ru) 2001-05-20
EE9800155A (et) 1998-12-15
NO982092L (no) 1998-06-29
WO1997017345A1 (fr) 1997-05-15
AU7500196A (en) 1997-05-29
NO309606B1 (no) 2001-02-26
UA50748C2 (uk) 2002-11-15
JP2000500125A (ja) 2000-01-11
JP4263240B2 (ja) 2009-05-13
ES2135934T3 (es) 1999-11-01
TR199800827T2 (xx) 1999-02-22
IL124364A (en) 2001-08-08
CZ142198A3 (cs) 1998-08-12
SI0863897T1 (en) 1999-10-31
CN1202169A (zh) 1998-12-16
NO982092D0 (no) 1998-05-07
EP0863897B1 (fr) 1999-06-16
ATE181328T1 (de) 1999-07-15
DE69602970D1 (de) 1999-07-22

Similar Documents

Publication Publication Date Title
EE9800155A (et) 5-fenüül-3-(piperidin-4-üül)-1,3,4-oksadiasol-2(3H)-ooni derivaadid kasutamiseks 5-HT4 - või H3- retseptorite ligandidena
PT946542E (pt) Derivados de indano ou de di-hidroindol
DE69325167D1 (de) Kondensierte indol-derivate als 5-ht4-rezeptor-antagonisten
PT871619E (pt) Derivados de fenil-tiazol com propriedades anti-virus do herpesc
DE69014028D1 (de) Kristalline Polyolefinmischung.
IL133960A0 (en) 2-(4-aryl or heteroaryl-piperazin-1-ylmethyl)-1h-indole derivatives
DE69801905D1 (de) 5-aryl-3-(8-azabicyclo[3.2.1]oct-3-yl)-1,3,4-oxadiazol-2(3h)-one derivate als 5-ht4 rezeptor liganden
FI890520L (fi) Foerfarande foer framstaellning av terapeutiskt anvaendbara 2- (piperidin-4-ylmetyl) -1,2,3,4 -tetrahydroisokinolinderivat.
DE58907381D1 (de) Ungesättigte Derivate von 2,2,6,6-Tetramethylpiperidin.
DK0863897T3 (da) Derivater af 5-phenyl-3-(piperidin-4-yl)-1,3,4-oxadiazol-2(3H)-on, som kan anvendes som ligander for 5-HT4- eller H3-recept
FR2741070B1 (fr) Derives de 5-phenyl-3-(piperidin-4-yl)-1,3,4-oxadiazol-2(3h) -one, leur preparation et leur application en therapeutique
FR2741069B1 (fr) Derives de 5-phenyl-3-(piperidin-4-yl)-1,3,4-oxadiazol-2(3h) -one, leur preparation et leur application en therapeutique
FR2745574B1 (fr) Derives de 5-phenyl-3-(piperidin-4-yl)-1, 3, 4-oxadiazol-2 (3h)-one, leur preparation et leur application en therapeutique
BR9510036A (pt) Derivados de 1,3,4-oxadiazina
EP0820578A4 (en) Electrothermal chemical cartridge
FR2759699B1 (fr) Derives de 5-(2,3-dihydro-1,4-benzoxazin-5-yl)-3-(piperidin- 4-yl)-1,3,4-oxadiazol-2(3h)-one, leur preparation et leur application en therapeutique
FR2763068B1 (fr) Derives de 3-(pyrrolidin-3-yl)-1,3,4-oxadiazol-2(3h)-one, leur preparation et leur application en therapeutique
AU7658798A (en) 5-phenyl-1,3,4-oxadiazol-2(3h)-one derivatives and their use as 5-ht4 ligands
FR2763067B1 (fr) Derives de 3-(1-azabicyclo[2.2.2] oct-3-ylalkyl)-1,3,4- oxadiazol-2(3h)-one, leur preparation et leur application en therapeutique
NO996580D0 (no) 5-(2-etyl-2H-tetrazol-5-yl)-1-metyl-1,2,3,6- tetrahydropyridinmaleat
KR970031762U (ko) 조작력이 향상된 힌지브라켓트를 구비한 아암레스트
FR2763069B1 (fr) Derives de 1,3,4-oxadiazol-2(3h)-one, leur preparation et leur application en therapeutique
DK1133494T3 (da) 8-Azabicyclo[3.2.1]oct-2-en-derivater
RU95116902A (ru) Средство для повышения резистентности организма
BR9104505A (pt) Maquina seletora de graos ou semelhantes

Legal Events

Date Code Title Description
PC Transfer

Free format text: SANOFI-SYNTHELABO (FR)

FB36 Technical and formal requirements: requirement - article 36 of industrial property law
HJEG Technical examination (opinion): technical examination (opinion) related to article 229 of industrial property law
FF Decision: intention to grant
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B25D Requested change of name of applicant approved

Owner name: SANOFI-AVENTIS (FR)

Free format text: ALTERADO DE: SANOFI-SYNTHELABO

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 18A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2278 DE 02-09-2014 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.